New combo shows promise for aggressive breast cancer
NCT ID NCT02689427
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a combination of enzalutamide (a hormone blocker) and paclitaxel (chemotherapy) given before surgery to 24 people with a specific type of triple-negative breast cancer that has androgen receptors. The goal was to see if this treatment could shrink tumors and reduce the amount of tissue needing removal. The trial is complete, and results will help guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Enzalutamide and paclitaxel
What this could lead to
If successful, this combination could offer a new treatment option for a hard-to-treat breast cancer type, potentially shrinking tumors before surgery and improving outcomes.
What could go wrong
This is a small, early-phase study with only 24 participants. Results may not apply to all patients, and side effects from chemotherapy and hormone therapy are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIA BREAST CANCER AJCC V6 AND V7 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
MD Anderson West Houston
Houston, Texas, 77079, United States